Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of CP-4055 in Chemotherapy-Naive Metastatic Melanoma
2005-000690-22Phase 2Completed
- Sponsor
- Clavis Pharma
- Start
- Jun 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elacytarabine in melanoma, sponsored by Clavis Pharma. Primary endpoint: Objective tumor response. Started Jun 2005; status: completed.
02
Drugs
elacytarabine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2005-000690-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000690-22.